HSBC analysts have recently boosted their recommendation on Merck shares (NYSE: MRK) to a Buy rating, moving up from a previous Hold. This upgrade is accompanied by a maintained price target of $130. The analysts base this decision on Merck’s strategic approach towards imminent patent expirations and its robust position in oncology.
Merck’s strategy focuses on extending the earnings potential of its oncology portfolio. This is especially significant given the company’s expertise in oncology and a strong clinical pipeline. As clinical successes become evident, analysts expect increased recognition of Merck’s pipeline value.
In 2025, Merck faces several notable opportunities, the stabilisation of Gardasil’s revenue in China could be a significant contributor, the progress on subcutaneous formulations of Keytruda could provide additional market advantages, and the introduction of Winrevir presents further growth prospects
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
HSBC’s analysis of Merck highlights a balanced view of imminent opportunities and risks. The upgrade to a Buy rating reflects confidence in Merck’s strategic direction and its capacity to manage upcoming challenges effectively. While risks remain, particularly related to its product pipeline and market conditions, Merck’s efforts in oncology and strategic innovations signify positive long-term prospects.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
